EXPLORE!

FDA Approves Kisunla

  431 Views

Emedinexus    02 June 2025

The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for treating Alzheimer’s disease. Kisunla is recommended for use in patients with mild cognitive impairment or mild dementia, as these were the stages studied in the clinical trials.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.